Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 60,527,316
  • Shares Outstanding, K 211,560
  • Annual Sales, $ 12,274 M
  • Annual Income, $ 2,539 M
  • 36-Month Beta 0.75
  • Price/Sales 4.95
  • Price/Cash Flow 10.62
  • Price/Book 4.83

Price Performance

See More
Period Period Low Period High Performance
1-Month
283.97 +0.30%
on 02/22/18
370.57 -23.14%
on 01/26/18
-62.83 (-18.07%)
since 01/22/18
3-Month
283.97 +0.30%
on 02/22/18
370.57 -23.14%
on 01/26/18
-24.99 (-8.07%)
since 11/22/17
52-Week
244.28 +16.59%
on 05/31/17
370.57 -23.14%
on 01/26/18
-2.82 (-0.98%)
since 02/22/17

Most Recent Stories

More News
What's in the Cards for Ionis (IONS) This Earnings Season?

Ionis Pharmaceuticals (IONS) earns $70 million in milestone and license payments from several drug companies. Spinraza witnesses strong fourth quarter as announced by Biogen in its earnings release.

GEMP : 6.79 (+1.65%)
IONS : 49.88 (+0.04%)
ATRA : 42.90 (-1.72%)
BIIB : 284.81 (-0.45%)
Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M

Ionis Pharmaceuticals (IONS) out-licenses Generation 2.5 antisense drug to AstraZeneca under a strategic collaboration agreement.

AZN : 33.69 (-0.41%)
IONS : 49.88 (+0.04%)
GSK : 36.57 (-1.69%)
BIIB : 284.81 (-0.45%)
Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat

Acorda (ACOR) misses on earnings in Q4 but beats on revenue estimates. The company's key drug Ampyra witnesses an increase in sales both year over year and sequentially.

XOMA : 25.35 (-2.50%)
EXEL : 29.10 (+0.38%)
ACOR : 26.40 (+1.15%)
BIIB : 284.81 (-0.45%)
FDA Sets the Stage for Earlier-Stage Alzheimer's Treatments

FDA's proposed guidelines come in a week when major disappointments in the field were announced by companies developing drugs to treat Alzheimer's.

MRK : 54.57 (+0.04%)
LLY : 77.19 (-0.46%)
PFE : 35.74 (-0.06%)
BIIB : 284.81 (-0.45%)
Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates

Alkermes (ALKS) tops earnings and sales estimates in the fourth quarter of 2017 on the back of strong growth of Vivitrol and Aristada. The company provided a decent outlook for 2018.

XOMA : 25.35 (-2.50%)
EXEL : 29.10 (+0.38%)
ALKS : 56.55 (-10.51%)
BIIB : 284.81 (-0.45%)
The New England Journal of Medicine Publishes SPINRAZA(R) (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy

--The majority of individuals treated with SPINRAZA demonstrated benefits in upper limb and general motor function, including crawling and standing with support

IONS : 49.88 (+0.04%)
BIIB : 284.81 (-0.45%)
Merck (MRK) Halts Another Late Stage Study on Alzheimer's

Merck (MRK) stalls a phase III study evaluating verubecestat for the treatment of prodromal Alzheimer's disease on the recommendation of an external data monitoring committee.

MRK : 54.57 (+0.04%)
LLY : 77.19 (-0.46%)
PFE : 35.74 (-0.06%)
BIIB : 284.81 (-0.45%)
3 ETFs to Watch on Biotech Earnings

Major Biotech companies report mixed Q4 results.

IBB : 108.42 (-0.61%)
BBH : 121.36 (-0.76%)
BIB : 57.11 (-1.13%)
GILD : 79.40 (-1.60%)
AMGN : 182.45 (+0.01%)
ALXN : 114.59 (-2.14%)
BIIB : 284.81 (-0.45%)
3 ETFs to Watch on Biotech Earnings

Major Biotech companies report mixed Q4 results.

IBB : 108.42 (-0.61%)
BBH : 121.36 (-0.76%)
BIB : 57.11 (-1.13%)
GILD : 79.40 (-1.60%)
AMGN : 182.45 (+0.01%)
ALXN : 114.59 (-2.14%)
BIIB : 284.81 (-0.45%)
The Zacks Analyst Blog Highlights: Novartis, BP and Biogen

The Zacks Analyst Blog Highlights: Novartis, BP and Biogen

NVS : 85.20 (+0.37%)
BP : 39.25 (+1.06%)
BIIB : 284.81 (-0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 294.84
1st Resistance Point 289.82
Last Price 284.81
1st Support Level 281.88
2nd Support Level 278.96

See More

52-Week High 370.57
Fibonacci 61.8% 322.33
Fibonacci 50% 307.42
Fibonacci 38.2% 292.52
Last Price 284.81
52-Week Low 244.28

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.